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Abstract
Background: Poor nutrition in the first months after oesophago-gastric resection is a contributing factor to the
reduced quality of life seen in these patients. The aim of this pilot and feasibility study was to ascertain the
feasibility of conducting a multi-centre randomised controlled trial to evaluate routine home enteral nutrition in
these patients.
Methods: Patients undergoing oesophagectomy or total gastrectomy were randomised to either six weeks of
home feeding through a jejunostomy (intervention), or treatment as usual (control). Intervention comprised
overnight feeding, providing 50 % of energy and protein requirements, in addition to usual oral intake. Primary
outcome measures were recruitment and retention rates at six weeks and six months. Nutritional intake, nutritional
parameters, quality of life and healthcare costs were also collected. Interviews were conducted with a sample of
participants, to ascertain patient and carer experiences.
Results: Fifty-four of 112 (48 %) eligible patients participated in the study over the 20 months. Study retention at
six weeks was 41/54 patients (76 %) and at six months was 36/54 (67 %). At six weeks, participants in the control
group had lost on average 3.9 kg more than participants in the intervention group (95 % confidence interval [CI]
1.6 to 6.2). These differences remained evident at three months (mean difference 2.5 kg, 95 % CI −0.5 to 5.6) and at
six months (mean difference 2.5 kg, 95 % CI −1.2 to 6.1). The mean values observed in the intervention group for
mid arm circumference, mid arm muscle circumference, triceps skin fold thickness and right hand grip strength
were greater than for the control group at all post hospital discharge time points. The economic evaluation suggested
that it was feasible to collect resource use and EQ-5D data for a full cost-effectiveness analysis. Thematic analysis of 15
interviews identified three main themes related to the intervention and the trial: 1) a positive experience, 2) the reasons
for taking part, and 3) uncertainty of the study process.
Conclusions: This study demonstrated that home enteral feeding by jejunostomy was feasible, safe and acceptable to
patients and their carers. Whether home enteral feeding as ’usual practice’ is a cost-effective therapy would require
confirmation in an appropriately powered, multi-centre study.
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Background
Weight loss and poor nutritional intake is frequently ob-
served after oesophagectomy for cancer.. Ryan et al. [1]
estimated that at hospital discharge after oesophagect-
omy, oral intake was sufficient to meet only 65 % of esti-
mated energy requirements. A recent review identified
between 5 % and 12 % weight loss at six months after
surgery with more than half of patients losing more than
10 % of preoperative weight [2]. In the studies to report
long-term outcome [3, 4], at five years or more after sur-
gery, between 49 % and 95 % of patients had failed to re-
gain lost weight postoperatively. This suggests that the
early deleterious effects on weight and nutrition have a
sustained and durable effect. Whether better weight
maintenance in the early months translates into long-
term benefit is unknown.
Several centres have reported on the value of home
enteral feeding in selected patients after oesophagectomy
[5–11]. Feeding in this setting has largely been restricted
to patients with early nutritional failure or anastomotic
complications that mandate an extended period of no
oral intake. The practice of routine home enteral feeding
after oesophagectomy has not been established.
The frequency of jejunostomy placement at the time
of oesophagectomy varies widely between centres [12].
Within the UK, some centres place a jejunostomy in
fewer than a quarter of patients undergoing resection,
while other centres place a jejunostomy in over three
quarters of patients. The 2010 UK National Oesophago-
gastric Cancer Audit identified that overall 68 % of the
2,200 patients undergoing oesophagectomy during the
time period of October 2007 to June 2009 had a feeding
jejunostomy placed [12]. Twenty-eight percent had no
feeding adjunct and the remaining 4 % of patients had
an alternative adjunct, such as a nasojejunal tube. In
addition to heterogeneity in the practice of tube place-
ment, there are variations in the feeding infusion regi-
mens, with each centre adopting its own local policy.
It is possible that the observed heterogeneity in prac-
tice stems from the rare but serious in-hospital compli-
cations associated with jejunostomy tube placement and
feeding. A review of published series indicates a revision
laparotomy rate of 0.9 % (range 0 to 3 %) [13]. These re-
late to small bowel necrosis, perforation, obstruction or
feed tube migration into the peritoneal cavity. None oc-
curred after hospital discharge, suggesting that it is safe
to discharge patients home with the tube in place.
The physical, psychological and emotional conse-
quences of living with a feeding jejunostomy tube and
the associated feeding are unknown, from both the pa-
tient and carer perspectives. Studies of patients receiving
home feeding via gastrostomy tubes suggest that the
tube itself and the associated regimen may impose a bur-
den of treatment [14–16].
The objective of this study was to pilot an investiga-
tion of the impact of six weeks of home jejunostomy
feeding in patients undergoing oesophagectomy or total
gastrectomy for cancer, and therefore to assess the feasi-
bility of conducting a subsequent appropriately powered
multi-centre trial.
Methods
The study protocol has previously been published in full
[17]. A summary is provided below.
Study design
This was a prospective two-arm randomised controlled
pilot and feasibility trial, with a nested qualitative study,
comparing six weeks of home jejunostomy feeding
(intervention) with treatment as usual (control). Given
the nature of the intervention and control, it was not
possible to blind participants or those responsible for
patient care. To minimise bias, the research dietitians
(MB, VH) who collected study data had no involvement
in patient care.
Participants and setting
The study recruited adult patients referred to the Uni-
versity Hospitals of Leicester NHS Trust Oesophago-
gastric Cancer Service, Leicester, United Kingdom with
confirmed diagnoses of oesophageal or gastric cancer.
Inclusion criteria were planned elective oesophagectomy
(transhiatal, Ivor Lewis, three-stage) or total gastrectomy
with placement of feeding jejunostomy tube. Patients
undergoing subtotal gastrectomy were excluded, as it is
not our usual practice to place feeding jejunostomy
tubes in this patient group.
Recruitment and ethics
Potential participants were identified at the weekly
multidisciplinary, upper gastro-intestinal cancer meet-
ings by a team member involved in the patient’s care. At
the surgical clinic visit, potential participants were asked
by a member of the healthcare team whether they were
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happy to receive information about the study. If they
agreed, they were provided with a participant informa-
tion leaflet and asked to give their consent for a member
of the research team to contact them by telephone.
A minimum of 24 hours later a member of the re-
search team contacted the potential participant by tele-
phone. If they agreed to take part, the patient was visited
in hospital at their pre-assessment clinic appointment.
Written informed consent was obtained from all trial
participants.
Research Ethics Committee approval for the study was
granted by the Nottingham Local Research Ethics Com-
mittee 2, Nottingham, NG1 6FS (protocol 11/EM/0383)
in January 2012. Recruitment commenced in July 2012
and closed in March 2014. Participant follow-up was
completed in September 2014.
Randomisation
Participants were randomised to control or intervention
group at enrolment, and prior to surgery, so that base-
line quality of life and nutritional parameters could be
collected. The randomisation schedule was managed by
the University of Leicester Clinical Trials Unit (hosted
by Sealed Envelope Ltd), using computer-generated ran-
dom assignment, using permuted blocks, stratified for
type of procedure (oesophagectomy or total gastrec-
tomy). A member of the Research Team (Dietitian or
Lead Clinician) randomised the participant through an
electronic interactive web response system (IWRS). Par-
ticipants were entered into the study sequentially, and
the IWRS provided a trial participation number.
Standard postoperative care
All participants received standard postoperative care
while in hospital, consisting of feeds, via the jejunostomy
tube, placed at time of surgery. Tube insertion, com-
mencement of feeds and subsequent increase in volume
followed a previously agreed care pathway [17]. Continu-
ous jejunostomy feeds were reduced to supplementary
overnight feeds (10 – 15 hours duration) when oral in-
take recommenced after surgery (at approximately post
operative day 7). Overnight feed continued until the
morning of the day of hospital discharge in all partici-
pants. Dietary advice, including food fortification and
the use of prescribable nutritional supplements, with
supporting written information, was provided to all pa-
tients, prior to discharge, by the clinical team.
Intervention
Participants randomised to the intervention arm were
referred to the local Home Enteral Nutrition Service and
taught (with or without carer support) to independently
manage the jejunostomy feed at home. The intention
was to administer overnight jejunostomy feeds via an
electronic pump for the first 6 weeks after discharge
from hospital. The goal of supplementary jejunostomy
feeding was to provide at least 50 % of energy and pro-
tein requirements.
Control
Participants randomised to the control group received
routine clinical care. This comprised discontinuation of
jejunostomy feeds on the day of hospital discharge. The
tube was left in situ until outpatient review at week six
after discharge. As per usual practice, home jejunostomy
feeds were recommenced when deemed necessary by the
clinical team or Home Enteral Nutrition dietitian.
The criteria for recommencing feed comprised weight
loss of greater than 5 % from baseline level, reduced
functional status or estimated oral calorie intake <33
% of requirements.
Outcome measures
The primary outcome measures were recruitment rate
to the study and retention rates at six weeks and six
months post baseline. These measures were selected to
determine whether or not an appropriately powered de-
finitive trial would be possible.
The secondary outcome measures, recorded at hos-
pital discharge, six weeks after discharge, three months
after surgery and six months after surgery, focused on
nutritional status and quality of life, specifically:
i. the nutritional parameters of weight, body mass
index, upper arm anthropometry, and grip strength
ii. nutritional intake including total energy (kcal/day)
and protein intake (g/day), contribution of oral
intake (food, fluids), oral nutritional supplements
and jejunostomy feed (to be reported elsewhere)
iii. generic (EORTC QLQ-C30 [18]) and disease-specific
(EORTC QLQ-OG25 [19]) quality of life measures,
in order to assess the variability of these measures
and the relationship between generic and disease-
specific measures
iv. cost-effectiveness, derived from the EQ-5D-3 L [20]
quality of life instrument (measured at three and six
months post baseline) and the healthcare costs for
the duration of the study period
v. jejunostomy tube complications
vi. hospital readmission rates
vii.Participants’ and their carers’ experiences of living
with a feeding jejunostomy tube and home feeding.
Data analysis
Key elements of the data analysis plan have been re-
ported previously [17].
The proportion of eligible patients who consented to
participate were calculated, along with the proportions
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in each intervention group completing six weeks and six
months of assessments. Hospital readmission rates were
summarised by intervention group.
The analysis was performed on the full analysis set,
analysing according to group assigned by randomisation.
The full analysis set comprised all patients who were
randomised to one of the trial interventions and who
had post randomisation endpoint data recorded, regard-
less of the actual intervention the patient received, and
regardless of protocol deviations or completion of the
trial. Additionally, some sensitivity analyses were per-
formed in which patient groups were analysed according
to whether or not they received the jejunostomy feeding
while being randomised to intervention or control. As
the likely outcome measure for the multi-centre trial will
be quality of life, point estimates and variability of each
of the quality of life measures were determined by inter-
vention group (assuming either different or same stand-
ard deviations). As this was a pilot and feasibility study,
it was not powered to detect differences between the
two groups. Accordingly, formal hypothesis testing has
not been conducted.
The differences in EQ-5D-3 L, EORTC QLQ-C30
and EORTC QLQ-OG25 between the groups, with as-
sociated 95 % CI, were calculated at three weeks after
hospital discharge, three months after surgery and six
months after surgery, based on ANCOVA analyses to
adjust for type of surgery and baseline value of EORTC
QLQ-C30. The EQ-5D-3 L was summarised using the
UK time trade-off (TTO) value set. For OG25, the
summary outcome of all questions was determined,
while for C30 the focus was on the quality of life
questions.
Sample size
As this was a feasibility study, the sample size was se-
lected in order to enable a sensible estimation of the
quantities of interest, in particular variability, while not
exposing too large a number of participants to the full
range of experimental procedures. The intention was to
recruit 60 participants, 30 randomised to receive home
jejunostomy feeding and 30 to receive treatment as
usual. This made allowance for a 17 % early withdrawal
rate, which would result in 50 participants completing
the six-week intervention period.
Qualitative study
Potential participants for the qualitative exploratory
study were those recruited into the main trial, and
their carers. Purposive sampling was undertaken in
order to ensure a representative selection of cases,
stratifying for gender, age, cohabiting status and
treatment group. Face-to-face semi-structured inter-
views were conducted by one of the researchers
(VH), with the aim of exploring the experiences of
people with oesophago-gastric cancer and their carers
regarding living with a jejunostomy tube. More spe-
cifically relating to the feasibility of the randomised
controlled trial, participants were asked to describe
their experiences of taking part in the study. Inter-
views lasted between 21 and 75 minutes; they were
audio-recorded and then transcribed verbatim. Fol-
lowing familiarisation with the data, an inductive the-
matic analysis was conducted with cross-checking of
themes between two members of the research team
(MB and VH). Field notes made following each inter-
view were also taken into consideration during the
analysis stage.
Results
Over the 20-month recruitment period, 112 eligible pa-
tients were screened for inclusion in the study. Fifty-four
agreed to participate, a recruitment rate of 48 %. This
represented 90 % of the projected sample size. Twenty-
six participants were randomised to the intervention
arm, while 28 participants were randomised to the con-
trol arm. Baseline and pre-intervention characteristics
are summarised in Table 1.
Figure 1 shows the disposition of patients throughout
the study. Study retention at six weeks was 41 partici-
pants (41/54, 76 %); it was 36 of 54 participants (67 %)
at six months. Seven of the 21 participants (33 %) in the
control group required home enteral feeding during the
first six weeks after discharge. One was discharged from
hospital on planned feeding because of a small anasto-
motic leak managed non-operatively. Six participants
recommenced home enteral feed on the direction of the
clinical team, because of greater than 5 % weight loss
from baseline or hospital discharge value and deteriorat-
ing functional status. Sixteen participants, eight in the
intervention group (total home feeding duration: 54–172
days) and eight in the control group (total home feeding
duration: 70–133 days). All had discontinued feeding by
six months.
Tables 2 and 3 show the EORTC QLQ-C30 and QLQ-
OG25 quality of life scores for the two groups. The glo-
bal quality of life scores deteriorated in both groups after
surgery, but approached baseline levels in both groups
by six months. A similar pattern is noted in the disease-
specific QLQ-OG25 scores. Estimates of the standard
deviation for the QLQ-C30 scores were 23, 22 and 21 at
six weeks after hospital discharge, three months after
surgery and six months after surgery respectively. Simi-
lar values for EORTC QLQ-OG25 scores were 15, 15
and 14 respectively.
Table 4 summarises the nutritional measures for the
two groups. At six weeks, participants in the control
group had lost on average 3.9 kg more than participants
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in the intervention group (95 % CI 1.6 to 6.2). These dif-
ferences remained evident at three months (mean differ-
ence 2.5 kg, 95 % CI −0.5 to 5.6) and at six months
(mean difference 2.5 kg, 95 % CI −1.2 to 6.1). At six
weeks, the mean difference in BMI between the con-
trol and intervention groups was 1.3 kg/m2 (95 % CI
0.6 to 2.1).
The mean values observed in the intervention group
for mid arm circumference, mid arm muscle circumfer-
ence, triceps skin fold thickness and right hand grip
strength were greater than for the control group at all
post hospital discharge time points (Table 4).
The hospital readmission rates during the first six
weeks after discharge from hospital were 6 of 20 partici-
pants (30 %) in the intervention group and 5 of 21 par-
ticipants (24 %) in the control group. The corresponding
figures for the time period between six weeks after dis-
charge and three months postoperatively were 2 of 18
(11 %) for the intervention group and 4 of 21 (19 %) for
the control group. During the last three months of the
study period, the readmission rates were 1 of 16 (6 %)
for the intervention group and 2 of 21 (9 %) for the con-
trol group.
Table 5 summarises the observed jejunostomy com-
plications, both in hospital and out of hospital. The
only two major (Clavien-Dindo grade 3b or greater)
jejunostomy tube- or feed-related complications oc-
curred in hospital, prior to commencement of the
home feeding schedule [21]. These two participants
in the control arm, who had undergone total gastrec-
tomy, required laparotomy and small bowel resection
for feed-related small bowel necrosis. There were no
major (Clavien-Dindo grade 3b or greater) tube- or
feed-related complications after discharge from hos-
pital [21]. Table 6 summarises the in-hospital out-
come (prior to commencement of the intervention
period).
Economic evaluation
The generic health-related quality of life was measured
using EQ-5D-3 L. The mean EQ-5D score was slightly
lower in the intervention group than in the control
group (Table 7).
Complete data on resource use were available for 45
participants at baseline (24 control, 21 intervention), 41
participants at six weeks after discharge from hospital
(21 control, 20 intervention) and 36 participants at six
months after surgery (21 control, 15 intervention), sug-
gesting that data collection using cost questionnaires
was feasible.
The mean cost per patient in the intervention arm was
£ 3450 and in the control arm was £3,519 (Table 7). This
difference was largely accounted for by an in-patient stay
Table 1 Participant characteristics
Intervention
(n = 20)
Control
(n = 21)
Sex
Male 18 (90 %) 18 (86 %)
Female 2 (10 %) 3 (14 %)
Age in years 64.6 (8.0) 63.1 (8.7)
Body mass index at baseline (kg/m2) 27.0 (4.9) 28.4 (4.2)
Percentage weight loss from diagnosis
to visit 1
−0.8 (10.5) −1.2 (9.2)
Tumour location
Lower third oesophagus 13 (65 %) 14 (67 %)
Cardia 6 (30 %) 5 (24 %)
Linitis plastica 1 (5 %) 2 (10 %)
Neoadjuvant chemotherapy 20 (100 %) 18 (86 %)
UICC stage
0 0 (0 %) 1 (5 %)
1 3 (15 %) 2 (10 %)
2 3 (15 %) 9 (43 %)
3 13 (65 %) 9 (43 %)
4 1 (5 %) 0 (0 %)
T stage
Tis 0 (0 %) 1 (5 %)
T1 0 (0 %) 0 (0 %)
T2 4 (20 %) 4 (19 %)
T3 15 (75 %) 15 (71 %)
T4 1 (5 %) 1 (5 %)
N stage
N0 5 (25 %) 7 (33 %)
N1 8 (40 %) 12 (57 %)
N2 7 (35 %) 2 (10 %)
N3 0 (0 %) 0 (0 %)
Type of surgery
Transhiatal oesophagectomy 2 (10 %) 1 (5 %)
Ivor Lewis oesophago-gastrectomy 14 (70 %) 15 (71 %)
Total gastrectomy 4 (20 %) 5 (24 %)
Surgical approach
aOpen 8 (40 %) 8 (38 %)
Laparoscopic 12 (60 %) 13 (62 %)
ICU/HDU stay in days 6.2 (3.6) 6.0 (4.6)
Hospital stay in days 19.4 (6.7) 16.3 (6.8)
Values indicated are mean (standard deviation) for continuous measures, and
counts (percentages) for categorical measures
HDU high dependency unit, ICU intensive care unit, SD standard deviation, Tis
in situ carcinoma, UICC Union for International Cancer Control
aAll total gastrectomy and transhiatal oesophagectomy procedures were
performed through open access. Ivor Lewis oesophago-gastrectomy procedures
were performed through laparoscopic abdominal and open thoracic access.
Radiotherapy, either preoperative or postoperative, was not employed in
any participant
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of 16 days for one patient in the control arm six weeks
after discharge.
A mapping technique was used to link the outcomes
from EORTC QLQ-C30 onto the EQ-5D to inform
whether quality-adjusted life years (QALYs) could be
worked out from the EORTC QLQ-C30 for future study.
The results showed that the algorithm by McKenzie and
van der Pol [20], using the OLS model, did not accur-
ately predict the EQ-5D values.
Qualitative study findings
Fifteen interviews were conducted, between two and
three months post surgery. Twelve of the participants
were male and three female with eight interviews also
including a carer or partner, all of whom were female.
The mean age of the patients was 65 years (range 52 to
74 years). Ten of the 15 patient participants were mar-
ried or cohabiting. All participants had a jejunostomy
tube placed at the time of surgery that was then used in
the immediate postoperative course. Eleven of the 15
subsequently received home jejunostomy feeding, the
duration of which varied between 28 and 104 days.
Regarding the feasibility of conducting a randomised
controlled trial involving home jejunostomy feeding, the
interviews revealed three main themes: 1) a positive ex-
perience (15 participants), 2) the reasons for taking part
(11 participants), and 3) uncertainty of the study process
(9 participants). All participants described coping mech-
anisms for managing the feeding tube and high levels of
Fig. 1 CONSORT diagram indicating participant disposition
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compliance with jejunostomy tube care and the feeding
regimen. The in-depth experiences of the challenges and
motivators of living with a jejunostomy tube, and in par-
ticular the coping strategies that were described by pa-
tients and their carers, have been reported elsewhere [22].
The general consensus from all of the participants
was that it was ‘not a problem taking part’ in the
study. Interestingly, most patients (n = 8) voiced that
they were pleased to be in the group to which they
were randomised.
Table 2 EORTC QLQ-C30 quality of life scores
Absolute baseline QOL scores Six weeks after hospital
discharge (change)
Three months after surgery
(change)
Six months after surgery
(change)
Int (n = 20) Cont (n = 21) Int (n = 20) Cont (n = 21) Int (n = 18) Cont (n = 20) Int (n = 16) Cont (n = 20)
Global QOL 74 (22) 80 (17) −20 (37) −21 (16) −17 (29) −21 (22) −5 (25) −7 (18)
Physical 92 (10) 93 (15) −27 (20) −21 (20) −22 (21) −17 (21) −17 (21) −9 (21)
Role 85 (23) 90 (22) −47 (31) −41 (28) −43 (31) −36 (28) −17 (31) −19 (37)
Cognitive 84 (20) 91 (16) −9 (28) −6 (17) −5 (28) −2 (18) −13 (25) −6 (16)
Emotional 77 (22) 83 (20) −2 (17) −4 (19) −1 (15) −7 (15) 1 (19) −3 (16)
Social 87 (24) 86 (24) −34 (39) −34 (29) −34 (42) −24 (29) −13 (30) −15 (33)
Fatigue 13 (14) 17 (29) 37 (26) 28 (25) 34 (32) 27 (23) 27 (27) 16 (28)
Nausea & vomiting 9 (21) 8 (23) 19 (42) 10 (31) 19 (39) 19 (35) 13 (28) 10 (38)
Pain 4 (12) 13 (21) 24 (19) 9 (29) 18 (22) 7 (28) 15 (21) 1 (24)
Dyspnoea 3 (10) 3 (10) 33 (31) 19 (27) 31 (35) 22 (22) 23 (23) 10 (22)
Sleep disturbance 20 (29) 13 (20) 25 (42) 24 (32) 13 (43) 12 (25) 2 (43) 7 (32)
Appetite loss 13 (29) 19 (37) 57 (46) 32 (39) 48 (50) 25 (36) 17 (37) 13 (48)
Constipation 10 (19) 17 (34) −5 (16) −2 (41) 7 (27) 8 (43) 0 (21) −3 (40)
Diarrhoea 0 (0) 5 (12) 13 (20) 21 (29) 15 (21) 22 (27) 25 (26) 15 (20)
Financial impact 27 (40) 19 (31) −3 (34) 9 (26) −4 (32) 10 (27) −6 (37) 7 (30)
Values indicated are mean (standard deviation)
Cont control, Int intervention, QOL quality of life
Table 3 EORTC QLQ-OG25 quality of life scores
Absolute baseline QOL scores Six weeks after hospital
discharge (change)
Three months after surgery
(change)
Six months after surgery
(change)
Int (n = 20) Cont (n = 21) Int (n = 20) Cont (n = 21) Int (n = 18) Cont (n = 20) Int (n = 16) Cont (n = 20)
Body image 87 (23) 95 (16) −8 (32) −5 (24) −2 (33) −12 (33) 0 (24) −13 (29)
Dysphagia 82 (28) 84 (27) −3 (47) 0 (35) 4 (37) 4 (36) 12 (29) 7 (33)
Eating 73 (35) 72 (32) −24 (50) −6 (39) −12 (44) −3 (37) −2 (36) 3 (42)
Reflux 88 (27) 94 (11) −15 (39) −17 (30) −9 (35) −12 (22) −2 (12) −13 (27)
Odynophagia 84 (27) 79 (28) −7 (39) 7 (32) −3 (40) 7 (38) 0 (21) 8 (32)
Pain & discomfort 93 (13) 92 (17) −23 (22) −12 (20) −15 (28) −17 (32) −19 (27) −11 (28)
Anxiety 39 (20) 51 (30) 8 (31) 17 (34) 18 (28) 8 (24) 25 (30) 18 (35)
Eating with others 80 (37) 89 (27) 8 (43) 3 (21) 7 (42) 2 (30) 10 (38) 3 (37)
Dry mouth 67 (34) 71 (34) −15 (52) 2 (34) −7 (44) −2 (40) 0 (37) 8 (36)
Trouble with taste 82 (33) 76 (35) −33 (41) −16 (42) −20 (43) −12 (38) −17 (49) −8 (49)
Trouble swallowing saliva 88 (27) 92 (23) 3 (30) 5 (26) 11 (28) 7 (26) 8 (29) 3 (28)
Choked when swallowing 90 (19) 97 (10) 0 (31) 0 (15) 6 (17) −2 (13) 4 (17) −2 (7)
Trouble with coughing 75 (26) 79 (25) −28 (39) −13 (27) −24 (49) −7 (32) −15 (37) −5 (33)
Trouble talking 95 (16) 92 (18) −7 (28) 2 (17) −7 (31) 2 (17) 4 (17) 0 (31)
Weight loss 88 (22) 89 (19) −17 (45) −9 (24) −22 (44) −18 (23) −19 (37) −8 (30)
Hair loss 81 (21) 85 (34) 6 (25) −17 (28) −7 (15) 13 (38) 0 (0) −17 (24)
Values indicated are mean (standard deviation)
Cont control, Int intervention, QOL quality of life
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Table 4 Change in nutritional characteristics from baseline
Six weeks after hospital discharge Three months after surgery Six months after surgery
Intervention
(n = 20)
Control
(n = 21)
Intervention
(n = 18)
Control
(n = 21)
Intervention
(n = 16)
Control
(n = 21)
Weight (kg) −3.8 (3.5) −8.6 (4.7) −6.3 (5.1) −9.7 (5.7) −7.4 (5.2) −10.9 (7.2)
Weight (%) −4.6 (3.9) −9.7 (4.8) −7.4 (5.7) −10.9 (6.0) −8.9 (5.4) −12.2 (7)
Weight loss experienced from baseline
None 1 (5 %) 1 (5 %) 1 (6 %) 1 (5 %) 1 (6 %) 0 (0 %)
<5 % 12 (60 %) 2 (10 %) 8 (44 %) 2 (10 %) 3 (19 %) 3 (14 %)
5% to 10 % 5 (25 %) 8 (38 %) 3 (17 %) 5 (24 %) 4 (25 %) 4 (19 %)
>10 % 2 (10 %) 10 (48 %) 6 (33 %) 13 (62 %) 8 (50 %) 14 (67 %)
Mid arm circumference (cm) −2.1 (1.4) −2.8 (1.9) −2.4 (1.6) −2.9 (1.7) −2.6 (1.6) −3.1 (2.3)
Mid arm circumference (%) −6.2 (4.0) −8.4 (5.4) −6.9 (4.5) −8.7 (4.9) −7.6 (4.6) −9.1 (6.3)
Mid arm muscle circumference (cm) −2.1 (1.4) −2.8 (2.1) −2.4 (1.6) −2.9 (1.8) −2.6 (1.5) −3.1 (2.3)
Mid arm muscle circumference (%) −6.2 (4.8) −8.4 (7.1) −6.9 (5.5) −8.7 (6.1) −7.6 (4.9) −9.1 (7.4)
Triceps skin fold thickness (mm) −0.7 (2.1) −1.8 (2.2) −1.1 (2.3) −2.3 (2.3) −1.9 (2.7) −2.5 (2.7)
Triceps skin fold thickness (%) −2.7 (11.8) −8.2 (13.5) −2.7 (15.7) −12.0 (14.0) −8.7 (16.2) −11.6 (13.6)
Hand grip dynamometry (kg) −2.5 (4.4) −4.1 (4.9) −2.9 (4.6) −4.1 (4.3) −1.5 (4.4) −2.0 (4.1)
Hand grip dynamometry (%) −6.9 (12.6) −11.4 (12.7) −7.8 (14.5) −11.9 (11.3) −3.5 (12.7) −5.2 (10.4)
Values indicated are mean (standard deviation)
Table 5 Comparison of 1minor jejunostomy complications for the two groups
Minor jejunostomy complications 2Intervention (n = 22) 3Control (n = 23)
In hospital
Any jejunostomy complication (%) 11 (50 %) 7 (30 %)
Diarrhoea (%) 2 (9 %) 3 (13 %)
Reflux of feed/vomiting (%) 0 (0 %) 0 (0 %)
Tube displacement or migration (%) 0 (0 %) 1 (4 %)
Inadvertent tube removal (%) 1 (4 %) 1 (4 %)
Tube fracture (%) 0 (0 %) 0 (0 %)
Leakage around insertion site (%) 5 (23 %) 1 (4 %)
Tube occlusion (%) 4 (18 %) 3 (13 %)
2Functional jejunostomy at hospital discharge 20 21
Out of hospital Intervention (n = 20) Control (n = 21)
Any jejunostomy complication (%) 11 (55 %) 14 (67 %)
Diarrhoea (%) 4 (20 %) 3 (14 %)
Reflux of feed/vomiting (%) 2 (10 %) 0 (0 %)
Tube displacement or migration (%) 1 (5 %) 0 (0 %)
Inadvertent tube removal (%) 3 (15 %) 5 (24 %)
Tube fracture (%) 0 (0 %) 0 (0 %)
Leakage around insertion site (%) 4 (20 %) 4 (19 %)
Tube occlusion (%) 2 (10 %) 2 (9 %)
Functional jejunostomy at end of six weeks (%) 16 (80 %) 16 (76 %)
1Indicates Clavien-Dindo grade 1 or 2 complications
2One participant had a non-functioning jejunostomy tube and one participant underwent gastric mobilisation with jejunostomy placement, but did not proceed
to resection
3One participant had a non-functioning jejunostomy tube, and for one participant the jejunostomy fell out
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“Fortunately, for me, anyway, I was one of those that
didn’t have to [be fed]…… Beforehand, it didn’t really
mean an awful lot, but I was relieved afterwards,
yeah, when I found that out.”
“I wouldn’t have liked that [being in the control
group], I would have thought that that was wasting
my time, so I’m glad that I’m in the one …… I think
that just feeding people for 6 weeks like that has got to
be a good thing. It takes all the worry out of it for both
staff and patients and it’s no big deal.”
None of the participants found the additional visits by
the research team to be burdensome. Only one negative
comment was made regarding the assessment tools. This
related to the difficulty in completing the quality of life
questionnaire and the dilemma of feeling ‘well’ but know-
ing that you have cancer. Most of the participants (n = 11)
spoke about why they had taken part in the study. In some
cases (n = 8) this was for altruistic reasons as well as the
hope that it would improve their wellbeing.
“I thought well, you know, if it benefits people, well
even if it benefits me, which I think it has done, and if
it benefits people in the long term I think it’s a good
thing.”
For one patient it was because she thought that it
would mean that she received better care.
“Well I was hoping I was going to be in it because me
son said they take more notice of you, take more care
of you.”
Finally, there were a number of comments from par-
ticipants (n = 9) that suggested that despite having the
information sheet and giving consent, they did not fully
understand the study process.
“I wonder, this may not be true at all , but I did
wonder it passed through my head when I knew I was
Table 6 Comparison of in-hospital course for the two groups
Intervention (n = 22) Control (n = 23)
Abdominal sepsis
Radiological drainage (%) 0 (0 %) 0 (0 %)
Other non-operative (%) 0 (0 %) 0 (0 %)
Return to operating theatre (%) 1 (4.5 %) 2 (9 %)
Anastomotic leak
Radiological drainage (%) 0 (0 %) 2 (9 %)
Other non-operative (%) 1 (4.5 %) 3 (13 %)
Return to operating theatre (%) 2 (9 %) 1 (4 %)
Cardiac complication
Arrhythmia (%) 4 (18 %) 2 (9 %)
Cardiac failure (%) 0 (0 %) 0 (0 %)
Chylothorax
Non-operative (%) 1 (4.5 %) 0 (0 %)
Return to operating theatre (%) 2 (9 %) 0 (0 %)
Haemorrhage
Blood transfusion (%) 1 (4.5 %) 0 (0 %)
Return to operating theatre (%) 1 (4.5 %) 0 (0 %)
Pneumonia/pleural effusion
Intercostal drain placement (%) 3 (13 %) 3 (13 %)
Re-ventilation (%) 2 (9 %) 4 (17 %)
Renal complication (%) 0 (0 %) 0 (0 %)
Surgical site infection
Superficial infection (%) 5 (23 %) 2 (8 %)
Deep infection (%) 2 (9 %) 4 (17 %)
Thromboembolic disease
Deep venous thrombosis (%) 1 (4.5 %) 0 (0 %)
Pulmonary embolism (%) 0 (0 %) 0 (0 %)
In-hospital mortality (%) 1 (4.5 %) 0 (0 %)
Table 7 Cost per patient by group and EQ-5D score
Cost per patient Intervention Standard care Mean difference
Baseline £ 2,451.58 (3,535.33) £ 1,669.57 (2,004.62) £ 782.01
Six weeks £ 2,438.00 (2,440.52) £ 1,795.74 (2,422.75) £ 642.26
Six months £ 1,012.49 (1042.42) £ 1,723.61 (2,681.00) £ -711.12
Total cost £ 3,450.49 £ 3,519.35 £ -68.86
EQ-5D score Intervention Standard care Mean difference
Baseline 0.800 (0.181) 0.825 (0.202) −0.025
Six weeks 0.599 (0.239) 0.643 (0.255) −0.044
Six months 0.686 (0.201) 0.735 (0.274) −0.049
Values indicated are mean (standard deviation)
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in this particular group……was I put in to this group
actually because I made such a good recovery?”
“I just came home…. and then all of a sudden the
research dietitian phones up and says ‘when are you
coming in?’ and I said ‘what for?’ she said ‘for this
study’. I said ‘oh, am I on it then?’”
Discussion
The aim of most previous studies of jejunostomy feeding
after oesophago-gastric resection has been to determine
whether preoperative or in-hospital feeding would influ-
ence in-hospital outcome measures, such as postopera-
tive complications or length of hospital stay [23–26].
These studies reported either no benefit or marginal
benefit in favour of in-hospital feeding. The current
study is the first randomised trial to compare a planned
programme of out-of-hospital enteral feeding to usual
care. The principal findings were that home feeding was
safe, acceptable to patients and their carers, and that it
might confer nutritional benefits. Ninety percent of the
projected 60 participants were recruited to the trial.
The relatively high non-completion rate of 33 % was
considerably greater than the projected 17 % [17], but
largely relates to participant enrolment before surgery.
In the planning of this study, the timing of enrolment
was one of the key considerations and discussion points.
It was agreed that recruitment should be before surgery
for several reasons. Firstly, this allowed baseline pre-
surgery information to be collected. Secondly, it pre-
vented the study team from biasing who would take part
based on postoperative course. Thirdly, the study man-
agement group, which included patient and carer repre-
sentatives, considered that patients convalescing after
surgery would not be well placed to deal with the
information-giving exercise and consenting for enrol-
ment in a clinical study. It was considered that this
might adversely affect recruitment and acceptability. The
recommendations for a definitive trial would be that re-
cruitment be likewise before surgery.
The other finding that was not anticipated was the
relatively high requirement for recommencement of
home feeding in the control group, at 33 %. The study
was set up, anticipating that 15–20 % of participants in
the control arm would require ’rescue‘ feeding [17]. One
possible explanation for this observation is the high level
of dietetic support offered to patients at our centre. It
may be that the threshold for restarting home feeding as
’usual treatment‘ is lower than at other centres, although
pre-defined criteria were used as triggers for restarting
feeding.
The demographics of the sample were as expected,
with a male preponderance and a mean age around 65
years. In the study, the groups were stratified for type of
surgery (oesophagectomy versus total gastrectomy)
because of concerns about the differing effect of the two
operations on weight loss and quality of life. No direct
comparison of the outcomes of participants undergoing
oesophagectomy has been made with those of partici-
pants undergoing total gastrectomy. The rationale for
stratifying the trial based on type of surgery was on the
premise that the type of reconstruction after total gas-
trectomy might have an independent effect on weight
and quality of life. For a definitive trial, we consider that
such stratification would be required. The alternative ap-
proach would be to enter a homogeneous group into a
larger scale study. This could be achieved by restricting
the inclusion criteria to patients undergoing Ivor Lewis
style oesophago-gastrectomy. The rationale for enrolling
patients undergoing total gastrectomy in the current
study was to make the findings as generalisable as pos-
sible, and also because this reflected our local practice of
placing feeding jejunostomy in patients undergoing these
operations.
During the study, one change was made to the proto-
col. The window of assessments for visit 4 was initially
set at 48 hours, but this proved impractical for patients
recruited around the time of public holidays, and this
time window was increased to 96 hours. Going forward,
it might prove easier to reference every assessment point
relative to one fixed point in time. In this study, two ref-
erence points were used: day of surgery and day of hos-
pital discharge. This meant that the interval between visit
3 (six weeks after hospital discharge) and visit 4 (three
months after surgery) varied considerably between partici-
pants. The initial intention had assumed a postoperative
hospital stay of two weeks. In those with a longer hospital
stay, the interval between these two visits was short.
Although it is gaining acceptance, there are compara-
tively few reports in the literature relating to home jeju-
nostomy feeding. There are wide variations in practice
between centres. Several studies have reported on the
use of home feeding on a selective basis. The indications
for feeding have been either the management of postop-
erative complications, such as anastomotic leak where a
prolonged period of no oral intake was required, or in
those with nutritional failure in the early months after
surgery. Ryan et al. [1] noted that 8 % of 205 patients
who had undergone oesophagectomy were discharged
from hospital on a planned programme of enteral feed-
ing, and that a further 6 % had restarted feeding within
the first month. Haverkort et al. [27] reported that 48 %
of 80 patients after oesophagectomy were discharged
home on planned feeding. By six months after surgery,
this figure had reduced to 2 % and by 12 months, a fur-
ther drop to 1 % was seen. Couper [6] reported that 19
% of 50 patients after oesophagectomy continued feeding
after discharge, principally for poor oral intake and that
a further 8 % restarted feeding later.
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The use of planned rather than selective feeding has
been reported in two small cohort studies. Tomascek et
al. [9] reported on an enhanced recovery protocol that
employed feeding exclusively via the jejunostomy for
four weeks in order to facilitate early hospital discharge.
Macharg et al. [11] demonstrated that home jejunostomy
feeding was associated with a 2-kg absolute (relative 4
%) weight benefit compared to no supplementation.
The economic evaluation suggested that the home en-
teral nutrition cost the NHS slightly less than standard
care. Although the cost difference was minimal, this
needs further exploring in a future cost-effectiveness
analysis, to ascertain whether the intervention is a cost
neutral or cost saving option.
Findings from the qualitative study suggested that par-
ticipants were happy to take part in this type of rando-
mised controlled trial, and that the intervention and
assessments were acceptable. Our findings around par-
ticipants having incomplete understanding of the re-
search process concur with those of previous work [28].
This highlights the importance of ensuring that re-
searchers are confident that participants are able to give
informed consent and fully understand, in particular, the
randomisation process. Understanding of the reasons
why patients agree to take part in a randomised con-
trolled trial, which in this case, and as found previously
[29], were mainly altruistic, may help optimise future
study design.
The current study has allowed recruitment (48 %) and
retention rates (76 % at six weeks, 67 % at six months)
to be determined. The intention was for this information
to inform a subsequent multi-centre, pragmatic rando-
mised controlled trial. In planning the pilot study, it was
envisaged that the primary endpoint for any subsequent
definitive trial would be a generic quality of life measure,
such as the QLQ-C30. Although not powered to detect
a difference between the two groups, it remains unclear
whether this remains an appropriate primary endpoint.
In order to identify a target difference between the con-
trol and intervention groups of 10 points [30], such a
trial would require 106 completing participants per
group, assuming a 90 % power and a 5 % significance
level. Allowing for 33 % early withdrawal and loss to
follow-up rate would require recruitment of 161 partici-
pants per group. It may be that a measure of physical
function is a more meaningful primary endpoint than
quality of life.
This study has demonstrated safety and acceptability of
home enteral feeding to patients and their caregivers. The
measured benefits included better weight, muscle and fat
store preservation. Quality of life measures were broadly
similar between the two groups. The additional healthcare
costs associated with home enteral feeding appeared to be
offset by reduced healthcare costs in other areas.
Conclusions
In conclusion, this study demonstrated that home enteral
feeding by jejunostomy was feasible, safe and acceptable
to patients and their carers. Whether home enteral feeding
as ’usual practice‘ is a cost-effective therapy would require
confirmation in an appropriately powered, multi-centre
study.
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